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In vivo investigation of antihyperalgesic and antinociceptive 
effects of peat formulations
The aim of this study is to evaluate the antihyperalgesic 
and antinociceptive effects of two formulations contain-
ing peat water extracts using a model of carrageenan-
-induced hyperalgesia, combined with a test with a me-
chanical stimulus, and a hot plate test. Rats were divided 
into seven groups (n = 6) and received local treatment 
with two peat formulations and two diclofenac formula-
tions dissolved in carbopol gel and Wolff® basis creme, 
respectively. Carbopol gel, Wolff® basis creme and 0.9 % 
NaCl without tested substances were used as controls. 
Both peat formulations exerted an unambiguous anti-
hyperalgesic effect 60 minutes after the treatment. In the 
hot plate test, the rats treated with the Wolff® basis creme 
peat formulation showed a tendency to prolonged latency 
on the first hour. The results could be explained by partial 
activation of peripheral α2-adrenoceptors and the possible 
COX-2 suppressive activity.
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Peat is a natural material characterized by a wide range of pharmacological effects 
and antibacterial (1), wound healing (2), antiviral properties (3). It has been found effective 
in the treatment of dermatitis, psoriasis and rheumatoid arthritis (2, 4). The most active 
components of the peat water extract are fulvic and ulmic acids (5). A clinical trial has 
proved the efficacy of fulvic acid in the treatment of eczema (6). Fulvic acid has been found 
to exhibit anti-inflammatory effects and wound healing properties in vivo (7). Our previ-
ous research showed that the peat water extract is a specific cyclooxygenase-2 (COX-2) 
inhibitor (8). Even though the anti-inflammatory effect of peat has been already reported, 
its effect on the hyperalgesia and nociception has not been studied enough.
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For the purposes of the present study, we selected two hydrophilic formulations, 
namely, a hydrogel and a hydrophilic cream, as delivery systems for the water-soluble 
compound found in peat.
The aim of this study is to evaluate the antihyperalgesic and antinociceptive effects of 
two formulations containing water extracts of peat. For these purposes, we used i) a model 
of carrageenan-induced hyperalgesia, combined with a nociceptive test with a mechanical 
stimulus, and ii) a nociceptive test with a thermal stimulus (hot plate test).
EXPERIMENTAL
Materials
The substances and marketed products used in the experiments and their respective 
producers and distributors are listed: peat (Wulfes Neudorf-Platendorf, Germany), aceto-
nitrile (Merck, Germany), trifluoroacetic acid (Sigma Chemical Co., USA), Carbopol 934 
(Sigma Aldrich, USA), triethanolamine (Alfa Aesar, USA), Wolff® basis creme (Dr. Wolff-
Gruppe GmbH, Germany), carrageenan (Fluka, Germany), diclofenac sodium (Ph. Eur.).
Animals
Male Wistar rats (weighing 125–250 g) were kept under standard laboratory condi-
tions (temperature 22 ± 1 °C, humidity 45 %, 12-h dark/light cycle, food, and water ad libi-
tum). The experiments were approved by the Bulgarian Food Safety Agency (permit num-
ber: 88/09.01.2014) and the Ethics Committee of the Medical University-Plovdiv, Bulgaria 
(approval number: 1/22.01.2015).
HPLC analysis of peat
The analysis was performed as described previously (1). Briefly, an HPLC-System of 
Perkin-Elmer (Arcade, USA) was used. The equipment consisted of an autosampler (ISS 200), 
diode array detector (Diode Array LC 235C), quaternary pump (Series 200 LC, Perkin-Elmer), 
column thermostat (LC Oven 101 CC5904762), gas removal equipment (Series 200 online de-
gasser), sample collector (FC 203B; Gilson, USA), and interface (600 Link, Perkin-Elmer). Pa-
rameters of the analytical column: Supelcosil RP C18 250 × 4.6 mm, 5 m (Supelco, USA). Mo-
bile phase A consisted of 99.95 % acetonitrile and 0.05 % trifluoroacetic acid (TFA). Mobile 
phase C consisted of 99.95 % water and 0.05 % TFA.
Sample preparation
Briefly, 20 g bidistilled water was added to 100 g fresh peat and a suspension was 
obtained. After one day storage at 25 °C, 1 g of this suspension was measured and centri-
fuged using a laboratory centrifuge 400R (Heraeus Instruments, Germany) for 20 min at 
3000 × g at 25 °C.
The supernatant was filtered (0.45 μm filter, Sartorius, Germany) and a clear, brownish 
liquid was collected. It did not show any sign of sedimentation at room temperature for 
several weeks or at a temperature of +2 °C for several days.
The samples (n = 5, volume = 25 mL) were subjected to evaporation at a pressure of 0.63 
mbar (63 N/m2) for 8 h at a temperature of +1 °C and the concentrated samples were centri-
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fuged at 25 °C and 3000×g for 10 min. The sediment was removed and the liquid was fil-
tered through a membrane filter (0.45 μm). A volume of 160 μL was injected into the HPLC 
system. All samples were examined at λ = (205 ± 5) nm.
Preparation of semisolid formulations
The water extract was concentrated and desiccated using a freeze dryer Alpha 1-4 (Martin 
Christ Gefriertrocknungsanlagen GmbH, Germany) until a concentration of 1 % (m/m) was 
obtained. Semisolid formulations were prepared with the desiccated water extract.
Preparation of carbopol gels
A required amount of Carbopol 934 (1 %, m/m) was dispersed in distilled water and 
the aqueous dispersion was allowed to hydrate for 2 hours. Propylene glycol (10 %, m/m) 
was added subsequently to the aqueous dispersion to prevent water loss. The carbopol 
dispersion was further neutralized with triethanolamine under gentle stirring and pH 
was adjusted to 6. A specific amount of the dried water extract (1 %, m/m) was dry ground 
in a mortar followed by wet grinding with the help of the prepared carbopol gel. The 
semisolid mixture was gently stirred with a spatula until a homogeneous gel was formed.
For the preparation of diclofenac gel, an accurately weighed amount of the non-steroi-
dal anti-inflammatory drug (NSAID) diclofenac (1 %, m/m) was dissolved in distilled water 
and the solution was added to the carbopol dispersion prior to neutralization.
Preparation of creams
A marketed Wolff® basis creme (WB creme) was used as the base for the preparation 
of peat/diclofenac cream formulations. A specific amount of dried water extract of peat /
diclofenac sodium (1 %, m/m) was ground in a mortar with the help of the base. The mix-
tures were gently stirred with a spatula until a homogeneous cream was formed. Three 
control groups were used in the experiment: saline (0.9 % NaCl), placebo carbopol gel and 
placebo WB creme for the two types of formulations, respectively. Formulations and the 
groups treated are shown in Table I.
Table I. Abbreviations and composition of the formulations used in the experiments
Group number Abbreviation Composition
1 control Saline (0.9 % NaCl)
2 carbopol Placebo carbopol gel 
3 WB creme Placebo Wolff® basis creme
4 PG Carbopol gel + water extract of peat
5 PC Wolff® basis creme + water extract of peat
6 DG Carbopol gel + diclofenac
7 DC Wolff® basis creme + diclofenac
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Forty-two rats were divided into seven groups (n = 6). Group numbers and their com-
position are given in Table I. Groups 6 and 7 were used as positive controls. The antihyper-
algesic effect of the formulations was tested on the same animals one day after the hot plate 
experiment. The rats received 1 mL of the formulations and the amount was spread solely 
on the skin of the rat’s right hind paw. The paw was massaged to allow skin penetration. 
An injection of 0.1 mL carrageenan (1 % (m/V) suspension in saline) was administered on 
the same paw after the treatment (9).
The pain threshold of the rats was tested with an Analgesy-Meter (Ugo Basile, Italy) 
immediately after the application of formulations. The right hind paw of the rat was sub-
jected to gradient increasing pressure (16 g s–1), which was applied to the paw between the 
third and fourth metatarsal joint. The point at which the rat withdraws the paw is the 
nociceptive threshold, measured in PPT-units. The cut-off limit of the apparatus is 250 g 
(maximum possible mechanical pressure). Subsequent measures were taken 60, 120 and 
180 minutes after the treatment.
Antinociception with thermal stimulus (Hot plate test)
The plantar surface of all rat paws was treated topically with the formulations described 
in Table I, and each rat received 1 mL of the formulation. Immediately before the application 
and 30, 60, 90 and 120 min after the treatment, the antinociceptive effect was studied using 
the hot plate test. The test was conducted as described before (10). The animals were placed 
on a metal plate (temperature of 55 ± 0.5 °C). Any sign of nociception (licking a hind paw, 
vocalization, or an escape attempt) was used as the endpoint of the test and the animal was 
returned to its cage. Latency was detected and reported as mean ± SEM. The cut-off time for 
the experiment was 30 s to minimize the risk of thermal injury of the paws.
Statistics
The SPSS 19.0 program was used for statistical analysis of the results. Normal distri-
bution was evaluated with a One-sample Kolmogorov-Smirnov test. All data showed nor-
mal distribution. One-way ANOVA and the Bonferroni post hoc test were performed. Data 
are shown as mean ± SEM. Results were considered significant at p < 0.05.
RESULTS AND DISCUSSION
HPLC analysis
As shown in Fig. 1, a well-defined peak with a retention time of 12.45 minutes was 
detected. The chromatographic profile of the water extract is similar to previously reported 
results (1). The fraction with a retention time of 12.45 min may exert an agonistic effect on 
dopamine D2 receptors and α2-adrenoceptors (5).
Antihyperalgesic effect
We registered a well-defined antihyperalgesic effect in the test with mechanical stimu-
lation in rats treated with both tested peat formulations – PG and PC at the 60th minute of 
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Fig. 1. Chromatographic profile (HPLC) of water extract of peat. Absorbtion at 205 nm.
Fig. 2. Evaluation of the antihyperalgesic effect of two peat formulations in rats (carrageenan-induced 
hyperalgesia). Data are shown as mean ± SEM (n = 6). 
**p < 0.01 vs. controls; ***p < 0.001 vs. controls; †p < 0.05 vs. carbopol; †††p < 0.001 vs. carbopol; !!p < 0.01 
vs. WB creme; !!!p<0.001 vs. WB creme; %%p < 0.01 vs. diclofenac+carbopol and diclofenac+WB creme; 
‡‡p < 0.01 vs. carbopol and WB creme; #p < 0.05 vs. peat+carbopol; §§§p < 0.001 vs. controls, carbopol, WB 
creme, peat+carbopol, peat+WB creme and diclofenac+carbopol.
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the experiment. The effect was diminished in the second hour. The rats treated with both 
diclofenac preparations showed increased PPT units in the second hour of the experi-
ment. The effect persisted to the third hour only in the DC group (Fig. 2). The results 
implicated that the antihyperalgesic effect of the water extract of peat reached its maxi-
mum at the 60th minute of the experiment, while the NSAID diclofenac was most active 
at the 120th minute.
Activation of primary sensory afferent neurons plays a major role in inflammatory 
pain. A wide range of inhibitory receptors (e.g. opioid, α-adrenergic, adenosine, 5-HT and 
GABAA) are present in the peripheral nerve endings (11).
The water extract of peat acts as a partial agonist of α2-adrenoceptors, as reported 
before (1). Activation of α2A- and α2C-adrenoceptors is involved in the antinociceptive effect 
(11). Moreover, Honda et al. (2015) reported that dexmedetomidine (a selective α2-
adrenoceptor agonist) diminished the hyperalgesic effect of carrageenan when injected 
locally into an inflamed hind paw of rats (12). The effect was abolished by local injection 
of yohimbine, which supports the suggestion of involvement of peripheral α2-adrenoceptors 
in the antihyperalgesic effect of dexmedetomidine.
It was previously reported that the peat water extract could act as a selective COX-2 
inhibitor (8, 13). These results suggest that the mechanism of the antihyperalgesic effect of 
the peat water extract is more complex and involves not only partial activation of periph-
eral α2-adrenoceptors but also COX-2 inhibition.
It has been proved that both fulvic and ulmic acids possess selective permeability 
through human skin (1). Their concentrations in the formulations are sufficient to provide 
the antihyperalgesic effect, having agonistic activity on the peripheral α2-adrenoceptors.
Antinociception with thermal stimulus (Hot plate test)
As shown in Fig. 3, the formulations containing the NSAID diclofenac showed a well-
defined antinociceptive effect. Its peak was reached at the 60th (DG) and 90th minute (DC) 
after the treatment. At the 60th minute, a significant increase in the latency was detected 
in the DG group (19.57 ± 2.17) compared to the control group (9.92 ± 1.43) and WB creme 
group (8.38 ± 1.57) (Fig. 3). Increased latency was registered also in the DC group, when 
compared to the controls, carbopol and WB creme groups (22.08 ± 2.59 vs. 9.92 ± 1.43; 11.37 ± 
1.74 and 8.38 ± 1.57, respectively). A tendency of increased latency was also observed in the 
rats treated with peat formulations on the 30th and 60th minute; however, statistical signifi-
cance was not reached.
On the 90th minute after the application, the DG treatment increased latency compared 
to the controls, WB creme, and PG (20.45 ± 1.30 vs. 9.37 ± 1.42, 6.95 ± 0.60 and 9.30 ± 1.33, 
respectively). A significant antinociceptive effect was also shown by the group treated 
with DC compared to the controls, WB creme and PG (18.73 ± 2.24 vs. 9.37 ± 1.42, 6.95 ± 0.60 
and 9.30 ± 1.33, respectively).
The water extract of peat and its components fulvic and ulmic acids are characterized 
by partial agonistic activity on α2-adrenoceptors and dopamine D2 receptors. Magnusson 
et al. reported the involvement of dopamine D2 receptors in the dorsolateral striatum in 
nociception (14). 
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Activation of dopamine D2 receptors and α2-adrenoceptors could explain the ten-
dency of prolonged latency at the 60th minute in rats treated with PC. However, the results 
did not reach statistical significance, probably due to the relatively low concentrations of 
water-soluble fulvic and ulmic acids in the central nervous system. The hot-plate test is 
usually used for evaluation of the central antinociceptive activity of drugs on acute, non-
inflammatory, nociceptive pain (15). Moreover, dopamine and noradrenaline are not the 
only mediators with a crucial role in the nociception in the hot plate test (15).
CONCLUSIONS
The water extract of peat included in carbopol gel and WB creme exerts an unam-
biguous antihyperalgesic effect at the first hour after the treatment. The antihyperalgesic 
effect in carrageenan-induced hyperalgesia could be explained by the partial activation of 
peripheral α2-adrenoceptors and COX-2 inhibitory activity. The activation of dopamine D2 
receptors and α2-adrenoceptors may explain the tendency of prolonged latency in rats 
treated with peat + WB creme at the 1st hour in the hot plate test. However, the central 
antinociceptive effect of the topical peat formulation with higher fulvic and ulmic acids 
concentration is a subject of future experiments.
Fig. 3. Evaluation of the antinociceptive effect of two peat formulations (hot plate test). Data are 
shown as mean ± SEM (n = 6).
*p < 0.05 vs. controls; **p < 0.01 vs. controls; ††p < 0.01 vs. carbopol; !!p < 0.01 vs. WB creme; !!!p < 0.001 vs. 
WB creme; #p < 0.05 vs. peat+carbopol; ##p < 0.01 vs. peat+carbopol.
380




 1.  A. M. Beer, H. E. Junginger, J. Lukanov and P. Sagorchev, Evaluation of the permeation of peat 
substances through human skin in vitro, Int. J. Pharm. 253 (2003) 169–175; https://doi.org/10.1016/
S0378-5173(02)00706-8
 2.  C. E. J. van Rensburg, The antiinflammatory properties of humic substances: a mini review, 
Phytother. Res. 29 (2015) 791–795; https://doi.org/10.1002/ptr.5319
 3.  R. Klocking, B. Helbig and P. Wutzler, Untersuchungen zur antiviralen Aktivität von polyanioni-
schen Torfinhaltsstoffen in vitro und in vivo, Geburtsh. Frauenheilk. 60 (2000) 192.
 4.  S. Codish, M. Abdu-Shakra, D. Flusser, M. Fringer and S. Sukenik, Mud compress therapy for the 
hands of patients with rheumatoid arthritis, Rheumatol. Int. 25 (2005) 49–54; https://doi.org/10.1007/
s00296-003-0402-4
 5.  A. M. Beer, J. Lukanov and P. Sagorchev, Isolation of biologically active fractions from the water 
soluble components of fulvic and ulmic acids from peat, Phytomedicine 9 (2002) 653–666; https://
doi.org/10.1078/094471102321616490
 6.  J. J. Gandy, J. R. Snyman and C. E. van Rensburg, Randomized, parallel-group, double-blind, 
controlled study to evaluate the efficacy and safety of carbohydrate-derived fulvic acid in topical 
treatment of eczema, Clin. Cosmet. Investig. Dermatol. 4 (2011) 145–148; https://doi.org/10.2147/CCID.
S23110
 7.  R. Sabi, P. Very and C. E. J. van Rensburg, Carbohydrate-derived fulvic acid (CHD-FA) inhibits 
carrageenan-induced inflammation and enhances wound healing: efficacy and toxicity study in 
rats, Drug Dev. Res. 73 (2011) 18–23; https://doi.org/10.1002/ddr.20445
 8.  A. M. Beer, P. Zagorchev, M. Filipova and J. Lukanov, Effects of aqueous peat extract on the activ-
ity of cyclooxygenase and cyclooxygenase-1 and cyclooxygenase-2 isoforms, Phys. Med. Rehab. 
Kuror. 25 (2015) 51–54.
 9.  S. Porzio, G. Caselli, L. Pellegrini, V. Pallottini, M. Del Rosario, A. Coppola, L. Boltri, M. Gentile, 
G. Clavenna and G. Melillo, Efficacy of a new topical gel-spray formulation of ketoprofen lysine 
salt in the rat: percutaneous permeation in vitro and in vivo and pharmacological activity, Pharma-
col. Res. 37 (1998) 41–47; https://doi.org/10.1006/phrs.1997.0260
10.  E. G. Apostolova, V. Y. Kokova and L. P. Peychev, Experimental study on the antinociceptive effect 
of retigabine in rats, IJBAMR. 5 (2015) 568–574.
11.  R. M. Stepanović-Petrović, A. M. Micov, M. A. Tomić and N. D. Ugrešić, The local peripheral 
 antihyperalgesic effect of levetiracetam and its mechanism of action in an inflammatory pain 
model, Anesth. Analog. 115 (2012) 1457–1466; https://doi.org/10.1213/ANE.0b013e31826c7fc2
12.  Y. Honda, H. Higuchi, Y. Matsuoka, A. Yabuki-kawase, M. Ishii-maruhama, Y. Tomoyasu, S. Mae-
da, H. Morimatsu and T. Miyawaki, The inhibitory effect of locally injected dexmedetomidine on 
carrageenan-induced nociception in rats, Eur. J. Pharmacol. 764 (2015) 215–219; https://doi.
org/10.1016/j.ejphar.2015.06.054
13.  S. J. Chien, T. C. Chen, H. C. Kuo, C. N. Chen and S. F. Chang, Fulvic acid attenuates homocyste-
ine-induced cyclooxygenase-2 expression in human monocytes, BMC Complement. Altern. Med. 15 
(2015) 61; https://doi.org/10.1186/s12906-015-0583-xJ
14.  E. Magnusson and K. Fisher, The involvement of dopamine in nociception: the role of D(1) and 
D(2) receptors in the dorsolateral striatum, Brain Res. 855 (2000) 260–266; https://doi.org/10.1016/
S0006-8993(99)02396-3
15.  L. A. Pini, G. Vitale, A. Ottani and M. Sandrini, Naloxone-reversible antinociception by 
paracetamol in the rat, J. Pharmacol. Exp. Ther. 280 (1997) 934–940.
